Abstract
ABSTRACT
Twenty-eight monoclonal antibodies (MoAbs) from the NIH melanoma exchange program were analyzed in a binding assay for reactivity with a panel of 22 cell lines which included melanomas, carcinomas, fibroblasts, and lymphomyeloid cells. In this test, most MoAbs showed reactivity with a wide range of cell lines. The MoAbs were also tested for binding with freshly removed tumor cells and normal peripheral lymphocytes.
Get full access to this article
View all access options for this article.